PRODRUGS OF AXITINIB
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Mar 20, 2025
app pub date -
Oct 14, 2022
filing date -
Oct 14, 2022
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
In certain embodiments, the invention is directed to a compound of formula I: wherein: X1 is selected from N or N+Y1; X2 is selected from NH or NY2; X3 is selected from NH or NY3; Y is selected from —CH2OCO(OCH2CH2)n1OM1; or —CH2OCO(CH2)n1aCOOH; Y2 is selected from —CH2OCO(OCH2CH2)n2OM2; or —CH2OCO(CH2)n2aCOOH; Y3 is selected from —CH2OCO(OCH2CH2)n3OM3; or —CH2OCO(CH2)n3aCOOH; n1, n1a n2a, n3 and n3a are independently 0 or an integer from 1 to 8; M1, M2 and M3 are independently selected from H, optionally substituted C1-6alkyl and optionally substituted aryl wherein at least one of X1, X2 and X3 is not N or NH; and pharmaceutically acceptable salts thereof.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully